Pain, depression, and fatigue are the 3 most prevalent symptoms afflicting cancer patients. At some point in nearly every cancer patient's battle, at least 1 of these problems leads to significant personal disruption. But more commonly pain, depression, and fatigue occur together in the same patient. Their complex interactions seem to compound and magnify the distress they produce. With this clinical reality in mind, it is appropriate to expand our research efforts in the area of integrative interventions for these conditions. The widespread suffering associated with pain, depression, and fatigue warrants a careful exploration of nonpharmacological therapies that have demonstrated efficacy in well-designed studies. This is all the more essential given that pharmacological treatments by themselves have not come close to fully mitigating these troublesome symptoms.
On July 15-17, 2002, the National Institutes of Health (NIH) convened a state-of-the-science conference titled "Symptom Management in Cancer: Pain, Depression, and Fatigue." Sponsored by the National Cancer Institute and the Office of Medical Applications of Research of the NIH, the conference was cosponsored by, among other agencies, the National Center for Complementary and Alternative Medicine-an indication of the potential relevance of integrative treatments in addressing these conditions that are so widely experienced by cancer patients. A draft consensus statement, posted on the NIH Web site shortly after the conference, 1 identified research directions in these areas of major interest to integrative practitioners. We feel this official statement is of sufficient importance to bring it to the attention of all our readers.
Five problems were posed in the draft consensus statement: (1) the occurrence of pain, depression, and fatigue in cancer; (2) the methods for clinical assessment of these conditions; (3) the treatments available; (4) the impediments to effective symptom management in cancer patients experiencing pain, depression, or fatigue; and (5) the directions for future research. The statement points out that there are now 9 million cancer survivors in the United States alone. With 1.3 million new cancer diagnoses yearly, and an approximate 60% 5-year survival rate, the number of cancer survivors will continue to grow in the coming years and the number of patients coping with pain, depression, and fatigue during and following treatment will steadily increase. With an evolving recognition that therapies of nutrition, the mind and spirit, sleep hygiene, and physical care-including Eastern approaches of yoga, chi gong, and specific breathing techniques-it is apparent to many of us in the field of integrative cancer medicine that there is immense potential for making substantial contributions toward the alleviation of such widespread suffering.
The first problem to address in developing an effective means of managing such cancer problems is to know just how frequently these symptoms occur, for what duration, and with what intensity. As surprising as it may seem, we actually do not know with any accuracy how many people are experiencing pain, depression, fatigue, or, more likely, combinations of all 3 symptoms. Inconsistent estimates emerging from different studies attest to our very imprecise knowledge of any 1 symptom. For example, for those living with cancer, reports on the occurrence of pain vary anywhere from 14% to 100%, of depression from 1% to 42%, and of fatigue from 4% to an astonishing 92%. Certainly such widely varying findings reflect inconsistent measurements and methodologies, a lack of agreement on criteria for identifying symptoms, the impact of different research designs, and imprecisely defined study populations.
The second problem is the lack of agreed-upon instruments for assessing these conditions in a clinical setting and the lack of ongoing monitoring and measurement. More than 100 methods exist for pain assessment, from very simple to complex and multidimensional approaches. Two simple factors-severity of pain and degree of functional and emotional impairment due to pain-may suffice to determine need for treatment. Follow-up assessments that use new technology such as e-mail or telephone-based response systems may assist in ongoing pain management. Measurements of depression include such instruments as the Hospital Anxiety and Depression Scale for which clinically useful cutoff scores have been established. At present, however, few validated instruments exist for measuring fatigue, and much work remains to be done in this area.
The third problem cited in the report involves the development of more effective treatments for these symptoms in cancer patients and the evidence for their true benefits. The statement advocates the use of the World Health Organization 3-step analgesic ladder in pain management. Nonsteroidal anti-inflammatory Editorial drugs are used for the mildest pain, weak opiates for increased symptoms, and strong opiates for persistent or worsening pain. As most of us follow in our patient care, dosing around-the-clock may be more effective than as-needed dosing and may improve adherence to treatment and thus outcome. Some integrative medicine treatments such as hypnosis and other cognitive behavioral strategies have demonstrated value in pain management. Massage and other bodywork techniques, as well as assisting patients with sleep hygiene-not cited by the statement-offer significant benefit. Although treatment of depression in cancer patients with antidepressant medications has been validated in clinical trials, cognitive-behavioral or psychosocial interventions have also demonstrated significant benefits. This is particularly relevant for patients in need of regaining a sense of personal control and involvement in their clinical care. Additionally, there is a considerable need for research on integrative medicine methodology for depression among different populations of cancer patients. Finally, although fatigue may be the most prevalent of these cancer symptoms, this concern may have accrued the least amount of pertinent research on treatment methods. Evidence exists for correcting anemia-related fatigue through pharmacologic approaches such as erythropoietin alpha; exercise interventions may provide effective relief as well. By emphasizing a comprehensive lifestyle management of fatigue, this particular symptom should produce especially fruitful research involving integrative treatment.
Multiple, often interlocking factors produce impediments to true symptom management-the fourth problem identified in the consensus statement. Some of these develop out of obstacles to the reporting of symptoms by patients, whereas some are found and perpetuated within the medical system itself. A few of these include the belief that pain inevitably and inexorably accompanies cancer and that no truly effective relief is available. Also compounding this problem are fears among patients about opiate addiction, less than adequate clinical time and resources to address pain, and a lack of coordination of care among different providers, especially in the transition to hospice care. Depression too often goes unrecognized, and patients may be reluctant to report their true emotional distress due to the stigma of psychological symptoms. Physicians admittedly find themselves uncertain about both the diagnosis of depression and the effectiveness of available medications. Interestingly, depression itself may impair the ability of patients to advocate for their own interest. Additionally, obstacles to treatment for fatigue include lack of awareness of the prevalence of fatigue and the dearth of studies that urgently need to be done demonstrating successful treatment methods.
The fifth problem, the delineation of research directions, is explored from conceptual, methodological, treatment, and policy perspectives. For integrative practitioners and researchers, meaningful research pursuits include basic investigations on the prevalence of these symptoms in cancer and comparison populations; the development of simple and clinically useful screening strategies; psychological and physiological accommodations to these symptoms; new treatment plans, both pharmacological and nonpharmacological; and, not unimportantly, the investigation of the relationship between symptom management and adherence to cancer treatment. The multifaceted approaches of integrative medicine to the problems of pain, depression, and fatigue in cancer may provide truly innovative approaches to the improvement of quality of life among our cancer patients, but it may not stop at that. There are various indications that enhancing life quality may affect outcome as well. This may seem obvious to many of us, but until the pursuit of integrative research is further advanced, such questions will remain unanswered. In the name of putting patients' lives first, we urge attention to these integrative research directions.
In This Issue
Our lead article in this issue is by George J. Brewer, an emeritus professor of genetics at the University of Michigan, and Sofia D. Merajver of the University of Michigan Health System, who have turned their considerable talents to the exploration of a potential antiangiogenic agent for cancer, tetrathiomolybdate. This drug, originally developed for treatment of Wilson's disease, reduces the potential for angiogenesis by lowering copper levels. Both animal and human research indicate that copper is a potent mediator of many endogenous angiogenesis stimulators, and the research on tetrathiomolybdate indicates that copper lowering may be an effective antiangiogenic strategy. One particularly interesting facet of the article by Brewer and Merajver is the very large number of angiogenic stimulators they enumerate in emphasizing the complexity of the antiangiogenic strategy for cancer treatment. Stimulators range from proteases to oncogenes to a variety of other endogenous and exogenous modulators-and many interact with each other. Inhibition of cancer growth with a single antiangiogenic agent may be circumvented by activation of another angiogenic pathway, allowing the cancer to resume growth. Integrative medicine typically approaches clinical illness with carefully selected interconnecting and mutually enhancing interventions, taking advantage of additive effects while focusing on a broader context of each patient's health and survival. Although this approach is in conflict with current conceptions of pharmacology, which generally attempt to treat disease with a single "magic bullet" model, an integrative and comprehensive strategy may offer a much more productive approach to controlling diseases promoted by a multiplicity of mechanisms. The abundance of angiogenic stimulators highlights the potential benefits of the less conventional pharmacological approach of integrative medicine.
Integrative cancer therapy is not a field without controversies, and we do not intend to shy away from the exploration of such controversies in this journal. We present in this issue an article by Anna M. Tacón of Texas Tech University that explores the sensitive topic of whether deficits in parental attachment, particularly through early loss of parental figures, may have later effects on cancer susceptibility, particularly through the impact of such loss on the development of type C coping styles. Lydia Temoshok, originator of the model of type C coping, and Ruth Cohn Bolletino, a clinical psychologist and long-time colleague of Lawrence LeShan, have provided responses to this article, and we have also provided an editorial response to some of the controversies that arise in this exchange. Tacón's article and the accompanying responses drew considerable debate among our editorial staff. Challenging exchanges of this nature provide an important opportunity for evolving thought in any field. As editors, we are certainly looking forward to more discussion and debate on such controversial subject areas.
Many of our readers, however, will find that the article by Kevin Chen and Raphael Yeung is even more challenging than the article by Tacón. Their article concerns the impact of qigong, a traditional Chinese medicine (TCM) technique, on cancer. Although qigong is typically thought of as a useful exercise intervention, in the theories of TCM the manipulation of qi (vital essence or energy) may actually be able to affect the growth of cancers. Even more startling, TCM posits that experienced practitioners of qigong may be able to emit qi, a form of concentrated energy, from their bodies, and use it to "break apart cancers." This is certainly an unusual idea from a Western medicine point of view. To their credit, however, Chinese investigators have put their ideas to the test in numerous in vitro and in vivo studies on the effect of emitted qi on the growth of cancer cell lines. These experiments, along with a rather large number of clinical studies of the benefits of qigong for cancer patients, are published in the Chinese literature. Chen and Yeung very usefully review and comment on these studies, providing an overview of a significant body of literature that has heretofore been unavailable to those of us who do not read Chinese. We feel that, as unconventional as this literature might appear from Western standards, it is critical that its basic results and limitations be made available for the integrative medicine field to evaluate and consider. We would note, in addition, the publication of positive clinical studies of energy-based medical techniques such as micro-dose homeopathic remedies and therapeutic touch in mainline Western-based medical and oncology journals. [2] [3] [4] Raymond W. Pak and colleagues from the University of Medicine and Dentistry of New Jersey have provided a review of the findings behind the initiation of an important new clinical trial of selenium and vitamin E in prostate cancer. Although this journal is largely devoted to cancer treatment, we feel it is of special importance to devote space to cancer prevention, the only means by which all cancer suffering can ultimately be eradicated. Particularly interesting in the article by Pak and colleagues is the account of their initial experiences in recruiting patients to the trialsome of whom did not want to participate in the randomization due to a desire to receive the selenium and vitamin E supplements.
Our Integrative Tumor Board in this issue concerns what appears to be a recurrence of ovarian cancer. Terrence Bugno, a radiation oncologist who is also an integrative physician with a special interest in mindbody medicine and approaches to spirituality, provides radiation oncology perspectives. Medical oncologist Deva Nathan discusses chemotherapy options. Cancer recurrence is a tumultuous time for patients, as well as one of the areas in which psychooncology has a particularly significant role to play. Penny B. Block of the Block Center for Integrative Cancer Care discusses the use of specific depression, anxiety, and quality-of-life rating scales in the clinical context, again of interest in the light of the draft consensus statement. Daniel Labriola of the Northwest Natural Health Specialty Care Clinic in Seattle provides a naturopathic analysis. Chris Alvarado and Annette Chamness of the Chicago School of Massage Therapy discuss massage therapy for the case. Dietitian Natalie Lagomarcino of the University of California at San Francisco provides nutritional recommendations.
In this issue, we introduce another feature of Integrative Cancer Therapies, Research Briefings. Edited by Frank Alexander Hamill of the Southwest Foundation for Biomedical Research in San Antonio, Texas, this feature is written by Integrative Cancer Therapies staff. It features short summaries of research on topics of current interest in the field of integrative cancer medicine. Two may be of particular interest in this issue. One is a review of the recent clinical trials of St. John's wort in major depression, which also discusses the role Editorial INTEGRATIVE CANCER THERAPIES 1(4); 2002 of the placebo effect in clinical trials and current controversies in studies of placebo and related effects. Another is a short discussion of the role of insulin and insulin-like growth factors in colon cancer, a subject discussed in the Point-Counterpoint article in our June issue.
